Anixa Biosciences (ANIX) Projected to Post Earnings on Wednesday

Key Points

• Anixa Biosciences is expected to report Q3 2026 results before the market opens on September 9. Analysts project a loss of $0.08 per share, compared with a $0.07-per-share loss reported in the prior quarter that exceeded expectations.
• ANIX shares opened at $3.28 and are down 2.1%, with a 52-week range of $2.32 to $5.46 and a market capitalization of approximately $111.6 million.
• Analyst sentiment is mixed, with three Buy ratings, one Hold, and one Sell, producing an overall Hold consensus and an $8.50 average price target. Insiders have been buying shares, including a 21,000-share purchase by CEO Amit Kumar.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) is projected to post its Q3 2026 results before the market opens on Wednesday, September 9th. Analysts expect Anixa Biosciences to announce earnings of ($0.08) per share for the quarter. Parties may visit the the company's upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Wednesday, September 9, 2026 at 4:00 PM ET.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. On average, analysts expect Anixa Biosciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Anixa Biosciences Stock Down 2.1%

NASDAQ:ANIX opened at $3.28 on Wednesday. Anixa Biosciences has a 52 week low of $2.32 and a 52 week high of $5.46. The stock has a market capitalization of $111.59 million, a PE ratio of -10.58 and a beta of 0.51. The stock's 50-day moving average price is $3.33 and its 200-day moving average price is $2.98.

Insider Buying and Selling at Anixa Biosciences

In related news, CEO Amit Kumar purchased 21,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $52,500.00. Following the transaction, the chief executive officer directly owned 630,812 shares in the company, valued at approximately $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders have bought 50,024 shares of company stock worth $148,971. 26.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Anixa Biosciences

Several large investors have recently bought and sold shares of ANIX. Marshall Wace LLP acquired a new position in shares of Anixa Biosciences during the second quarter valued at approximately $39,000. NewEdge Advisors LLC purchased a new position in shares of Anixa Biosciences in the second quarter valued at approximately $33,000. Jane Street Group LLC boosted its stake in shares of Anixa Biosciences by 37.2% in the second quarter. Jane Street Group LLC now owns 41,800 shares of the company's stock worth $138,000 after acquiring an additional 11,340 shares during the last quarter. Benjamin Edwards Inc. acquired a new stake in shares of Anixa Biosciences in the second quarter worth approximately $37,000. Finally, Vanguard Group Inc. boosted its stake in shares of Anixa Biosciences by 2.1% in the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company's stock worth $4,694,000 after acquiring an additional 29,436 shares during the last quarter. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ANIX has been the subject of a number of analyst reports. Zacks Research cut Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. D. Boral Capital reissued a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, June 30th. Citigroup reaffirmed a "buy" rating on shares of Anixa Biosciences in a research note on Friday, June 12th. HC Wainwright reiterated a "buy" rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Finally, Wall Street Zen raised shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, June 20th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source